THRX has been successfully added into Your Stock Email Alerts list.
You can manage your stock email alerts here.
THRX has been removed from your Stock Email Alerts list.
Also See GuruFocus Insider Trade Screener:
| Insider | Position | Date | Buy/Sell | Shares | Shares Owned Following This | Trade Price ($) | Cost ($1000) | Price Change Since Trade (%) |
Details |
|---|---|---|---|---|---|---|---|---|---|
| Shafer Bradford J | Sr VP, Gen. Counsel, Secretary | 2013-06-07 | Sell | 31,038 | 306,166 | $35.04 | 1087.6 | 1.6 | Link |
| Brinkley David L | Head of Business Dev. | 2013-05-29 | Sell | 3,808 | 48,749 | $35.01 | 133.3 | 1.69 | Link |
| Brinkley David L | Head of Business Dev. | 2013-05-13 | Sell | 16,129 | 55,000 | $40.33 | 650.5 | -11.73 | Link |
| Brinkley David L | Head of Business Dev. | 2013-05-03 | Sell | 16,129 | 55,000 | $34.77 | 560.8 | 2.39 | Link |
| Winningham Rick E | CEO (Click for the stocks that their CEOs have bought) | 2013-04-30 | Sell | 255,532 | 721,551 | $33.64 | 8596.1 | 5.83 | Link |
| Aguiar Michael W | Sr VP, CFO | 2013-04-30 | Sell | 170,879 | 142,486 | $33.8 | 5775.7 | 5.33 | Link |
| Brinkley David L | Head of Business Dev. | 2013-04-30 | Sell | 17,104 | 55,000 | $33.76 | 577.4 | 5.45 | Link |
| Mammen Mathai | SVP, Research & Early Clin Dev | 2013-04-30 | Sell | 7,000 | 205,976 | $33.74 | 236.2 | 5.51 | Link |
| GLAXOSMITHKLINE PLC | 10% Owner | 2013-04-30 | Buy | 193,563 | 26,721,193 | $6.69922e+06 | 1296721120.9 | -100 | Link |
| Mammen Mathai | SVP, Research & Early Clin Dev | 2013-02-20 | Sell | 7,000 | 212,976 | $22.14 | 155 | 60.79 | Link |
| GLAXOSMITHKLINE PLC | 10% Owner | 2013-02-15 | Buy | 116,527 | 26,527,630 | $2.56709e+06 | 299135296.4 | -100 | Link |
| Mammen Mathai | SVP, Research & Early Clin Dev | 2012-11-02 | Sell | 7,000 | 205,641 | $21.45 | 150.2 | 65.97 | Link |
| GLAXOSMITHKLINE PLC | 10% Owner | 2012-11-02 | Buy | 280,348 | 26,411,103 | $6.26578e+06 | 1756598891.4 | -100 | Link |
| Aguiar Michael W | Sr VP, CFO | 2012-08-27 | Sell | 24,682 | 132,486 | $27.44 | 677.3 | 29.74 | Link |
| Brinkley David L | Head of Business Dev. | 2012-08-24 | Sell | 3,483 | 60,241 | $27.5 | 95.8 | 29.45 | Link |
| Mammen Mathai | SVP, Research & Early Clin Dev | 2012-08-13 | Sell | 25,000 | 212,285 | $25.74 | 643.5 | 38.31 | Link |
| Aguiar Michael W | Sr VP, CFO | 2012-08-07 | Sell | 60,000 | 157,924 | $27.04 | 1622.4 | 31.66 | Link |
| Winningham Rick E | CEO | 2012-08-03 | Sell | 75,749 | 591,258 | $27.95 | 2117.2 | 27.37 | Link |
| Brinkley David L | Head of Business Dev. | 2012-08-03 | Sell | 123,917 | 66,781 | $27.92 | 3459.8 | 27.51 | Link |
| GLAXOSMITHKLINE PLC | 10% Owner | 2012-08-03 | Buy | 316,334 | 26,130,755 | $28.21 | 8923.8 | 26.2 | Link |
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as Conversion of derivative security or Exercise of Options are not included. Insiders are only limited to Officers and/or Directors of the company.